Non-specific effects of vaccines on all-cause mortality: a meta-analysis of randomized controlled trials (RCTs) 2012-2025
Schou, J.; Hviid, A. P.; Petersen, E.; Simonsen, L.
Show abstract
BackgroundEarly observational studies reported substantial reductions in all-cause mortality, suggesting that childhood vaccines might influence health in ways beyond their targeted disease. Such Non-Specific Effects (NSEs) of vaccines could potentially have important implications for the Expanded Programme of Immunization (EPI). In 2014 World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) commissioned a review of the NSE evidence, which called for more Randomized Controlled Trials (RCTs). We aimed to review all RCTs published after this WHO-commissioned review. MethodsFollowing PRISMA guidelines, we searched systematically for RCTs published during 2012-2025. Inclusion criteria: children under 5 years and all-cause mortality as the primary outcome for any vaccine intervention. Risk estimates were pooled using a random effects model, reflecting the underlying hypothesis: that live-attenuated vaccines greatly reduce, and inactivated vaccines increase all-cause mortality. ResultsWe identified seven RCTs that fit the inclusion criteria, all of them of live-attenuated vaccines (Bacillus Calmette-Guerin, measles, and oral polio vaccine). In total, 52,596 participants were included across these studies. Five were conducted in Guinea-Bissau, one in Guinea-Bissau and Burkina Faso, and one in India. The RCTs were not blinded, and no placebo was used, consistent with a moderate risk of bias. Our meta-analysis found no significant evidence of NSEs (vaccine effectiveness 5%; -16% to 22%). One study of low birthweight newborns admitted to neonatal intensive care units in India found a small but statistically significant NSE (17%; 2% to 31%); interestingly the effect primarily played out in the first 3 days of the study, raising concern of bias. DiscussionThe meta-analysis of seven RCTs of live-attenuated vaccines found no evidence of significant NSE on all-cause mortality. This was also true when adding RCTs from before 2012 studying NSEs. In conjunction with the WHO-SAGE review, the current body of evidence on NSEs on all-cause mortality does not warrant a paradigm shift, nor does it provide a rationale for changing vaccine programs.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- What is the quality of evidence informing vaccine clinical practice recommendations in Australia? 96%
- Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review 94%
- A Meta-Analysis of Influenza Vaccination Following Correspondence: Considerations for COVID-19 94%
Similar papers in this journal
- A Systematic Review on Malaria and Tuberculosis (TB) Vaccine Challenges in Sub-Saharan African Clinical Trials 94%
- Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review 93%
- Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru 92%
Similar papers in this journal
- Non-specific effects of Bacillus Calmette-Guérin - a systematic review and meta-analysis of randomized controlled trials 96%
- Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression 95%
- Effectiveness of the WHO-authorized Covid-19 Vaccines: a Rapid Review of Global Reports till June 30, 2021 94%
Similar papers in this journal
- Pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: a retrospective record linkage cohort study 92%
- Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: a randomised, double-blind, non-inferiority trial 92%
- Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial 91%
Similar papers in this journal
- Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study 93%
- Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya 91%
- Impact of health system strengthening on delivery strategies to improve child immunization coverage and inequalities in rural Madagascar 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.